CandlesenseCandlesense
REGN•benzinga•

Sanofi Asthma Drug Misses Primary Goal, Plans For Pivotal Study

Summary

Sanofi reports amlitelimab improved lung function in asthma, with new phase 3 trials planned across its respiratory pipeline.

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on April 15, 2025 by benzinga

← Back to REGN News
    Sanofi Asthma Drug Misses Primary Goal, Plans For Pivotal Study | REGN Stock News | Candlesense